Zoetis Announces Second Quarter 2024 Results

Reports Revenue of $2.4 Billion, Growing 8%, and Net Income of $624 Million, or $1.37 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for Second Quarter 2024

Delivers 11% Operational Growth in Revenue and 18% Operational Growth in Adjusted Net Income for Second Quarter 2024

Reports Adjusted Net Income of $711 Million, or Adjusted Diluted EPS of $1.56, for Second Quarter 2024

Raises Full Year 2024 Revenue Guidance to $9.100 - $9.250 Billion, with Diluted EPS of $5.35 to $5.45 on a Reported Basis, or $5.78 to $5.88 on an Adjusted Basis

Increases Full Year 2024 Operational Revenue Growth to 9% to 11% and Full-Year Operational Growth in Adjusted Net Income to 13.5% to 15.5%

Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2024 and raised its guidance for full year 2024.

The company reported revenue of $2.4 billion for the second quarter of 2024, an increase of 8% compared with the second quarter of 2023. On an operational1 basis, revenue for the second quarter of 2024 increased 11% compared with the second quarter of 2023. Net income for the second quarter of 2024 was $624 million, or $1.37 per diluted share, a decrease of 7% and 6%, respectively, on a reported basis.

Adjusted net income2 for the second quarter of 2024 was $711 million, or $1.56 per diluted share, an increase of 9% and 11%, respectively, on a reported basis, and an increase of 18% and 20%, respectively, on an operational basis. Adjusted net income for the second quarter of 2024 excludes the net impact of $87 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.

EXECUTIVE COMMENTARY

“We had another outstanding quarter, demonstrating the strong demand for our trusted, innovative products, our ability to capture and expand markets, and the dedication of our purpose-driven colleagues," said Kristin Peck, Chief Executive Officer of Zoetis. “We achieved 12% revenue growth in the U.S. and 10% operational revenue growth internationally, with both our companion animal and livestock portfolios seeing impressive global operational growth, 12% and 9% respectively."

"Our excellent first half across key franchises, including osteoarthritis (OA) pain, Simparica and key dermatology, is a testament to our commitment to deliver breakthrough innovations that address our customers' unmet needs and our differentiated execution. I look forward to continuing our momentum into the second half of the year where we will remain focused on executing our strategy, building trust and preference for our best-in-class products and delivering value to shareholders.”

QUARTERLY HIGHLIGHTS

Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the second quarter of 2024:

Revenue in the U.S. segment was $1.3 billion, an increase of 12% compared with the second quarter of 2023. Sales of companion animal products increased 13%, driven by the company's monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela® for dogs and Solensia® for cats. Also contributing to growth in the quarter was Simparica Trio®, the company's flea, tick and heartworm combination product as well as the company's key dermatology portfolio, including Apoquel® and Cytopoint®. Sales of livestock products increased 11% in the quarter. Growth in both cattle and swine products was driven primarily by a soft prior year comparison due to the timing of supply of ceftiofur.

Revenue in the International segment was $1.0 billion, reflecting a 4% increase on a reported basis and an increase of 10% operationally compared with the second quarter of 2023. Sales of companion animal products grew 7% on a reported basis and 12% operationally. Growth in the quarter was driven by the company’s companion animal products, including Simparica® and Simparica Trio, key dermatology products, Apoquel and Cytopoint, as well as OA pain products, Librela for dogs and Solensia for cats. Sales of livestock products were flat on a reported basis and grew 8% operationally. Growth of the company's cattle and poultry products was driven largely by price increases in hyperinflationary markets. Sales of fish products grew due to increased demand for vaccines in Norway.

INVESTMENTS IN GROWTH

Zoetis continues to advance innovation and care for animals across the globe. Since its last quarterly earnings announcement, the company gained approval in Canada for Alpha Ject Micro® 7 ISA, the latest version of its combination vaccine for Atlantic Salmon, now enhanced with protection against Infectious Salmon Anaemia Virus (ISA). Simparica and Simparica Trio received approval in Canada for a claim related to the treatment and control of Asian longhorned tick infestations (Haemaphysalis longicornis) in dogs.

The company also received approval in Japan for Draxxin® KP (tulathromycin ketoprofen), an injectable for the treatment of bacterial pneumoniae in cattle. Fostera® Gold PCV MH, a one-shot vaccine for pigs that offers the longest lasting combined protection against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae infections, gained approval in Mexico for a claim related to breeding herd safety.

The company is further strengthening its Diagnostic offerings with the anticipated launch of a new premium point-of-care hematology analyzer, Vetscan® Opticell™, in the second half of 2024. As the newest addition to the Diagnostics suite, it offers veterinary healthcare teams significant time, cost and space savings – leading to better patient outcomes and a more efficient clinic. The innovative AI-powered classification technology will offer a more advanced option for Complete Blood Count (CBC) analysis, providing lab-quality accuracy at the point-of-care.

In June, Zoetis published its 2023 Sustainability Report, highlighting specific actions the company has made by embedding sustainability across the business to support Communities, Animals and the Planet as it advances sustainability in animal health for a better future.

FINANCIAL GUIDANCE

Zoetis is raising its full year reported 2024 guidance due to the company's strong first half and the underlying strength in companion animal.

Revenue between $9.100 billion to $9.250 billion (operational growth of 9% to 11%)
Reported net income between $2.450 billion to $2.490 billion
Adjusted net income between $2.640 billion to $2.690 billion (operational growth of 13.5% to 15.5%)
Reported diluted EPS of $5.35 to $5.45
Adjusted diluted EPS between $5.78 to $5.88

This guidance reflects foreign exchange rates as of late July. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call this morning.

WEBCAST & CONFERENCE CALL DETAILS

Zoetis will host a webcast and conference call at 8:00 a.m. (ET) today, during which company executives will review second quarter 2024 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. A replay of the webcast will be archived and made available on August 6, 2024.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.

1 Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange. 2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; expectations regarding timing and financial impact of divestitures; foreign exchange rates, tax rates and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share and operational results (which exclude the impact of foreign exchange), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.

Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com, as well as on LinkedIn, Facebook, X (formerly Twitter) and YouTube. We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.

ZTS-COR ZTS-IR ZTS-FIN

ZOETIS INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME(a)

(UNAUDITED)

(millions of dollars, except per share data)

Three Months Ended

Six Months Ended

June 30,

2024

2023

% Change

2024

2023

% Change

Revenue

2,361

2,180

4,551

4,180

Costs and expenses:

Cost of sales

668

607

1,311

1,195

Selling, general and administrative expenses

581

556

1,128

1,061

Research and development expenses

171

146

333

288

Amortization of intangible assets

(5)

(3)

Restructuring charges and certain acquisition and divestiture-related costs

Interest expense, net of capitalized interest

117

121

(3)

Other (income)/deductions–net

(104

)

(157

)

Income before provision for taxes on income

780

872

(11)

1,527

1,569

(3)

Provision for taxes on income

156

202

(23)

304

348

(13)

Net income before allocation to noncontrolling interests

624

670

(7)

1,223

1,221

—

Less: Net loss attributable to noncontrolling interests

—

)

—

)

Net income attributable to Zoetis Inc.

624

671

(7)

1,223

—

Earnings per share—basic

1.37

1.45

(6)

2.68

2.64

Earnings per share—diluted

1.37

1.45

(6)

2.67

2.64

Weighted-average shares used to calculate earnings per share

Basic

455.5

461.9

456.7

462.7

Diluted

456.0

462.9

457.4

463.8

(a) The condensed consolidated statements of income present the three and six months ended June 30, 2024 and 2023. Subsidiaries operating outside the United States are included for the three and six months ended May 31, 2024 and 2023.

* Calculation not meaningful.

ZOETIS INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars, except per share data)

Three Months Ended June 30, 2024

GAAP Reported(a)

Purchase Accounting Adjustments

Acquisition and Divestiture- Related Costs(1)

Certain Significant Items(2)

Non-GAAP Adjusted(b)

Cost of sales

668

)

—

667

Gross profit

1,693

—

1,694

Selling, general and administrative expenses

581

)

—

578

Amortization of intangible assets

(31

)

—

Restructuring charges and certain acquisition and divestiture-related costs

—

)

(37

)

—

Other (income)/deductions–net

—

(33

)

Income before provision for taxes on income

780

890

Provision for taxes on income

156

179

Net income attributable to Zoetis

624

711

Earnings per common share attributable to Zoetis–diluted

1.37

0.06

0.01

0.12

1.56

Three Months Ended June 30, 2023

GAAP Reported(a)

Purchase Accounting Adjustments

Acquisition and Divestiture- Related Costs(1)

Certain Significant Items(2)

Non-GAAP Adjusted(b)

Cost of sales

607

)

—

602

Gross profit

1,573

—

1,578

Selling, general and administrative expenses

556

)

—

549

Amortization of intangible assets

(31

)

—

Restructuring charges and certain acquisition and divestiture-related costs

—

)

—

Other (income)/deductions–net

(104

)

—

(10

)

Income before provision for taxes on income

872

(90

)

829

Provision for taxes on income

202

(34

)

178

Net income attributable to Zoetis

671

(56

)

652

Earnings per common share attributable to Zoetis–diluted

1.45

0.07

0.01

(0.12

)

1.41

(a) The condensed consolidated statements of income present the three months ended June 30, 2024 and 2023. Subsidiaries operating outside the United States are included for the three months ended May 31, 2024 and 2023.

(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.

See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

ZOETIS INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars, except per share data)

Six Months Ended June 30, 2024

GAAP Reported(a)

Purchase Accounting Adjustments

Acquisition and Divestiture- Related Costs(1)

Certain Significant Items(2)

Non-GAAP Adjusted(b)

Cost of sales

1,311

)

—

1,309

Gross profit

3,240

—

3,242

Selling, general and administrative expenses

1,128

)

—

1,122

Research and development expenses

333

)

—

332

Amortization of intangible assets

(63

)

—

Restructuring charges and certain acquisition and divestiture-related costs

—

)

(41

)

—

Other (income)/deductions–net

—

(35

)

(18

)

Income before provision for taxes on income

1,527

1,680

Provision for taxes on income

304

335

Net income attributable to Zoetis

1,223

1,345

Earnings per common share attributable to Zoetis–diluted

2.67

0.12

0.01

0.14

2.94

Six Months Ended June 30, 2023

GAAP Reported(a)

Purchase Accounting Adjustments

Acquisition and Divestiture- Related Costs(1)

Certain Significant Items(2)

Non-GAAP Adjusted(b)

Cost of sales

1,195

)

—

1,186

Gross profit

2,985

—

2,994

Selling, general and administrative expenses

1,061

(14

)

—

1,047

Amortization of intangible assets

(62

)

—

Restructuring charges and certain acquisition and divestiture-related costs

—

)

(24

)

—

Other (income)/deductions–net

(157

)

—

(65

)

Income before provision for taxes on income

1,569

(68

)

1,591

Provision for taxes on income

348

(32

)

334

Net income attributable to Zoetis

1,223

(36

)

1,259

Earnings per common share attributable to Zoetis–diluted

2.64

0.14

0.01

(0.08

)

2.71

(a) The condensed consolidated statements of income present the six months ended June 30, 2024 and 2023. Subsidiaries operating outside the United States are included for the six months ended May 31, 2024 and 2023. (b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

ZOETIS INC.

NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars)

(1)

Acquisition and divestiture-related costs include the following:

Three Months Ended

Six Months Ended

June 30,

2024

2023

2024

2023

Acquisition-related costs(a)

Divestiture-related costs(b)

—

Restructuring charges(c)

—

Total acquisition and divestiture-related costs—pre-tax

Income taxes(d)

Total acquisition and divestiture-related costs—net of tax

(a)

Acquisition-related costs represent external, incremental costs that directly relate to transacting and integrating businesses, included in Restructuring charges and certain acquisition and divestiture-related costs.

(b)

Divestiture-related costs represent external, incremental costs that directly relate to divesting and disintegrating businesses, included in Restructuring charges and certain acquisition and divestiture-related costs.

(c)

Restructuring charges represent employee termination costs directly related to acquisitions and divestitures, included in Restructuring charges and certain acquisition and divestiture-related costs.

(d)

(2)

Certain significant items include the following:

Three Months Ended

Six Months Ended

June 30,

2024

2023

2024

2023

Other restructuring charges and cost-reduction/productivity initiatives(a)

Certain asset impairment charges(b)

Loss on assets held for sale(c)

—

Net gain on sale of business(d)

—

(101

)

—

(101

)

Other

—

)

Total certain significant items—pre-tax

(90

)

(68

)

Income taxes(e)

(34

)

(32

)

Total certain significant items—net of tax

(56

)

(36

)

(a)

For the three and six months ended June 30, 2024, primarily consisted of employee termination costs related to organizational structure refinements, included in Restructuring charges and certain acquisition and divestiture-related costs. For the six months ended June 30, 2024, charges were partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.

For the three and six months ended June 30, 2023, primarily consisted of employee termination costs related to organizational structure refinements, included in Restructuring charges and certain acquisition and divestiture-related costs.

(b)

For the three and six months ended June 30, 2024, represents certain asset impairment charges related to our aquaculture business included in Other (income)/deductions–net.

For the three and six months ended June 30, 2023, represents certain asset impairment charges related to our precision animal health business, included in Other (income)/deductions–net.

(c)

Represents a loss on assets held for sale related to the planned sale of our medicated feed additive product portfolio, certain water soluble products and related assets, included in Other (income)/deductions–net.

(d)

Represents a net gain on the sale of a majority interest in our pet insurance business, included in Other (income)/deductions–net.

(e)

Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. For the three and six months ended June 30, 2023, also includes tax expense related to changes to prior years' tax positions with regard to the one-time mandatory deemed repatriation tax under the Tax Cuts and Jobs Act.

ZOETIS INC.

ADJUSTED SELECTED COSTS, EXPENSES AND INCOME(a)

(UNAUDITED)

(millions of dollars)

Three Months Ended

June 30,

% Change

2024

2023

Total

Foreign Exchange

Operational(b)

Adjusted cost of sales

667

602

as a percent of revenue

28.3

27.6

Adjusted SG&A expenses

578

549

Adjusted R&D expenses

171

146

—

Adjusted net income attributable to Zoetis

711

652

Six Months Ended

June 30,

% Change

2024

2023

Total

Foreign Exchange

Operational(b)

Adjusted cost of sales

1,309

1,186

as a percent of revenue

28.8

28.4

Adjusted SG&A expenses

1,122

1,047

Adjusted R&D expenses

332

288

—

Adjusted net income attributable to Zoetis

1,345

1,259

(10

(a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Income and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information.

(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.

ZOETIS INC.

2024 GUIDANCE

Selected Line Items

(millions of dollars, except per share amounts)

Full Year 2024

Revenue

$9,100 to $9,250

Operational growth(a)

9% to 11%

Adjusted cost of sales as a percentage of revenue(b)

Approximately 29.3%

Adjusted SG&A expenses(b)

$2,225 to $2,290

Adjusted R&D expenses(b)

$660 to $670

Adjusted interest expense and other (income)/deductions-net(b)

Approximately $200

Effective tax rate on adjusted income(b)

20.0% to 20.5%

Adjusted diluted EPS(b)

$5.78 to $5.88

Adjusted net income(b)

$2,640 to $2,690

Operational growth(a)(c)

13.5% to 15.5%

Certain significant items and acquisition and divestiture-related costs(d)

$80 - $90

The guidance reflects foreign exchange rates as of late July 2024.

Reconciliations of 2024 reported guidance to 2024 adjusted guidance follows:

(millions of dollars, except per share amounts)

Reported

Certain significant items and acquisition and divestiture-related costs(d)

Purchase accounting

Adjusted(c)

Cost of sales as a percentage of revenue

~ 29.4%

~ (0.1%)

~ 29.3%

SG&A expenses

$2,236 to $2,301

~ $(11)

$2,225 to $2,290

R&D expenses

$662 to $672

~ $(2)

$660 to $670

Interest expense and other (income)/deductions-net

~ $220

~ $(20)

~ $200

Effective tax rate

20.0% to 20.5%

Diluted EPS

$5.35 to $5.45

~ $0.19

~ $0.24

$5.78 to $5.88

Net income attributable to Zoetis

$2,450 to $2,490

$80 - $90

~ $110

$2,640 to $2,690

(a) Operational results (a non-GAAP financial measure) excludes the impact of foreign exchange.

(b) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. Adjusted cost of sales, adjusted SG&A expenses, adjusted R&D expenses, and adjusted interest expense and other (income)/deductions-net are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.

(c) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational results to the most directly comparable U.S. GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition and divestiture-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.

(d) Primarily includes certain nonrecurring costs related to acquisitions, divestitures and other charges.

ZOETIS INC.

CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES

(UNAUDITED)

(millions of dollars)

Three Months Ended

June 30,

% Change

2024

2023

Total

Foreign Exchange

Operational(b)

Revenue:

Companion Animal

1,649

1,489

Livestock

694

671

Contract Manufacturing & Human Health

(10

Total Revenue

2,361

2,180

U.S.:

Companion Animal

1,080

959

—

Livestock

228

206

—

Total U.S. Revenue

1,308

1,165

—

International:

Companion Animal

569

530

Livestock

466

465

—

Total International Revenue

1,035

995

Companion Animal:

Dogs and Cats

1,581

1,424

Horses

Total Companion Animal Revenue

1,649

1,489

Livestock:

Cattle

350

329

Poultry

132

131

Swine

130

133

Fish

Sheep and other

(23

(21

Total Livestock Revenue

694

671

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.

ZOETIS INC.

CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES

(UNAUDITED)

(millions of dollars)

Six Months Ended

June 30,

% Change

2024

2023

Total

Foreign Exchange

Operational(b)

Revenue:

Companion Animal

3,099

2,714

Livestock

1,414

1,429

Contract Manufacturing & Human Health

—

Total Revenue

4,551

4,180

U.S.:

Companion Animal

1,978

1,680

—

Livestock

493

490

—

Total U.S. Revenue

2,471

2,170

—

International:

Companion Animal

1,121

1,034

Livestock

921

939

Total International Revenue

2,042

1,973

Companion Animal:

Dogs and Cats

2,965

2,577

Horses

134

137

—

Total Companion Animal Revenue

3,099

2,714

Livestock:

Cattle

741

728

Poultry

271

270

—

Swine

257

275

Fish

107

101

Sheep and other

(31

(27

Total Livestock Revenue

1,414

1,429

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.

ZOETIS INC.

CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS

(UNAUDITED)

(millions of dollars)

Three Months Ended

June 30,

% Change

2024

2023

Total

Foreign Exchange

Operational(a)

Total International

1,035

995

Australia

Brazil

Canada

Chile

(21

(17

China

(19

(16

France

—

Germany

Italy

Japan

(17

(13

Mexico

Spain

United Kingdom

Other developed markets

138

125

Other emerging markets

222

203

(25

Six Months Ended

June 30,

% Change

2024

2023

Total

Foreign Exchange

Operational(a)

Total International

2,042

1,973

Australia

156

164

Brazil

200

175

Canada

136

120

Chile

(21

(17

China

144

186

(23

(20

France

Germany

109

—

Italy

Japan

(12

—

Mexico

Spain

—

United Kingdom

150

131

Other developed markets

265

247

Other emerging markets

450

418

(25

(a) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.

ZOETIS INC.

SEGMENT(a) EARNINGS

(UNAUDITED)

(millions of dollars)

Three Months Ended

June 30,

% Change

2024

2023

Total

Foreign Exchange

Operational(b)

U.S.:

Revenue

1,308

1,165

—

Cost of Sales

232

214

—

Gross Profit

1,076

951

—

Gross Margin

82.3

81.6

Operating Expenses

204

212

—

Other (income)/deductions-net

—

U.S. Earnings

872

739

—

International:

Revenue

1,035

995

Cost of Sales

342

315

—

Gross Profit

693

680

Gross Margin

67.0

68.3

Operating Expenses

175

166

Other (income)/deductions-net

—

)

International Earnings

518

515

(10

Total Reportable Segments

1,390

1,254

Other business activities(c)

(142

)

(116

)

Reconciling Items:

Corporate(d)

(299

)

(256

)

Purchase accounting adjustments(e)

(35

)

(43

)

(19

Acquisition and divestiture-related costs(f)

)

Certain significant items(g)

(70

)

Other unallocated(h)

(59

)

(53

)

Total Earnings(i)

780

872

(11

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.

(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.

(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.

(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.

(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.

(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, as well as a loss on assets held for sale and the impact of divestiture gains and losses.

(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.

(i) Defined as income before provision for taxes on income.

* Calculation not meaningful.

ZOETIS INC.

SEGMENT(a) EARNINGS

(UNAUDITED)

(millions of dollars)

Six Months Ended

June 30,

% Change

2024

2023

Total

Foreign Exchange

Operational(b)

U.S.:

Revenue

2,471

2,170

—

Cost of Sales

449

417

—

Gross Profit

2,022

1,753

—

Gross Margin

81.8

80.8

Operating Expenses

394

400

—

Other (income)/deductions-net

—

U.S. Earnings

1,628

1,353

—

International:

Revenue

2,042

1,973

Cost of Sales

655

606

—

Gross Profit

1,387

1,367

Gross Margin

67.9

69.3

Operating Expenses

334

317

Other (income)/deductions-net

—

International Earnings

1,053

1,050

—

(10

Total Reportable Segments

2,681

2,403

Other business activities(c)

(274

)

(230

)

Reconciling Items:

Corporate(d)

(587

)

(464

)

Purchase accounting adjustments(e)

(72

)

(85

)

(15

Acquisition and divestiture-related costs(f)

)

—

Certain significant items(g)

(76

)

Other unallocated(h)

(140

)

(118

)

Total Earnings(i)

1,527

1,569

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.

(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.

(i) Defined as income before provision for taxes on income.

* Calculation not meaningful.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240805847620/en/

Media Contacts: Jennifer Albano 1-862-399-0810 (o) jennifer.albano@zoetis.com

Laura Panza 1-973-975-5176 (o) laura.panza@zoetis.com

Investor Contacts: Steve Frank 1-973-822-7141 (o) steve.frank@zoetis.com

Nick Soonthornchai 1-973-443-2792 (o) nick.soonthornchai@zoetis.com

Zoetis (NYSE:ZTS)
過去株価チャート
から 7 2024 まで 8 2024